FB102 for adults with severe alopecia areata, compared with placebo
Tests FB102 against placebo in adults with severe or very severe alopecia areata.
Key facts
- Who runs it
- Forte Biosciences, Inc.
- Where
- Australia and New Zealand6 sites in 2 countriesChoose a country to see its sites
- Trial code
- Registry title
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 32 people, planned
- Started
- 23 Oct 2025
- Expected to end
- 10 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- FB102
- Placebo
- Record updated
- 20 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe to very severe alopecia areata, a condition where hair falls out in patches. It tests FB102 against a placebo (dummy drug).
- Age
- Men 18-60 years; women 18-75 years at Screening.
- Sex
- Men and women can join.
- Disease stage
- Severe to very severe alopecia areata with ≥50% scalp hair loss, including complete scalp hair loss (AT) or complete scalp, face and body hair loss (AU). Hair loss is measured by SALT score and checked by central photo review.
Main reasons for not taking part
- Hair loss from another cause, such as diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy or androgenetic alopecia.
- Other scalp diseases that affect the hair loss check, such as psoriasis, dermatitis or tinea capitis.
- Active whole-body diseases that cause hair loss, such as lupus, thyroiditis, systemic sclerosis, lichen planus or syphilis.
- The study center checks further rules not listed here.
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Males aged 18-60 years and females aged 18-75 years at Screening
- Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss; AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria
Who cannot take part
- Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy-induced hair loss, androgenetic alopecia)
- Other scalp diseases impacting AA assessment (e.g., psoriasis, dermatitis, tinea capitis)
- Active systemic diseases causing hair loss (e.g., lupus, thyroiditis, systemic sclerosis, lichen planus, syphilis); Note: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in Australia.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
The 2 groups in the trial
- FB102Existing treatment, for comparison
Participants will receive FB102.
- PlaceboPlacebo, for comparison
Matching placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
- Plain-language title
- FB102 for adults with severe alopecia areata, compared with placeboGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07205159, who can take part
- Record updated
- 20 November 2025